



Regd. Office : 109, Ghanshyam Enclave, Link Road, Laljipada, Kandivali (W), Mumbai : 400067.

Factory : Plot No. 9, 10, Phase II, Genesis Ind. Estate, Kolgaon, Palghar - 401 404. Maharashtra.

Contact No. : +91 9820201063 / 8080333319 / 8411879521

Email : influxhealthtech@gmail.com/ influxhealthcare1@gmail.com

Website : www.influxhealthtech.com

CIN : U24299MH2020PLC346825

March 5, 2026

To,
Listing Department,
National Stock Exchange Limited
Exchange Plaza, C-1, Block-G,
Bandra Kurla Complex, Bandra (E),
Mumbai-400 051

Scrip Code - INFLUX

Dear Sir/Madam,

Sub.: Intimation of Receipt of GMP Inspection Compliance Confirmation from Tanzania Bureau of Standards (TBS)

Ref.: Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform our stakeholders that **Influx Healthtech Limited ("the Company")** has received a confirmation on March 5, 2026 from the **Tanzania Bureau of Standards (TBS)** under the **Ministry of Industry and Trade, United Republic of Tanzania**, regarding the successful completion of a Good Manufacturing Practices (GMP) inspection at the Company's manufacturing facility.

The inspection was conducted by the Tanzania Bureau of Standards on December 9, 2025 at the Company's manufacturing plant located at Genesis Industrial Township, Kolgaon, Palghar, Maharashtra, India. Based on the inspection findings, evaluation of the production lines, and submission of Corrective and Preventive Actions, the authority has confirmed that the Company's facility complies with the **GMP acceptable requirements as per the Criteria for Good Manufacturing Practice for High-Risk Food Products**.

The authority has also indicated that the Company's food supplement products, subject to compliance with other applicable registration requirements, will be eligible for approval for registration in Tanzania.

This development is expected to support the Company's efforts in expanding its presence in international markets, particularly in Tanzania.



Regd. Office : 109, Ghanshyam Enclave, Link Road, Laljipada, Kandivali (W), Mumbai : 400067.

Factory : Plot No. 9, 10, Phase II, Genesis Ind. Estate, Kolgaon, Palghar - 401 404. Maharashtra.

Contact No. : +91 9820201063 / 8080333319 / 8411879521

Email : influxhealthtech@gmail.com / influxhealthcare1@gmail.com

Website : www.influxhealthtech.com

CIN : U24299MH2020PLC346825

The details as per requirement of Regulation 30 of Listing Regulations read with SEBI circular HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 is given in "Annexure A".

We request you to take the above information on record.

Thanking you,

For Influx Healthtech Limited,

Munir Abdul Ganee Chandniwala
Managing Director
DIN: 08459582

For Further Information, please contact



Company
Influx Healthtech Limited
Ashish Shah
Chief Financial Officer
cs@influxhealthtech.com



Investor Relations Consultants

Capital Bridge Advisory Service Private Limited

info@capbridge.in
079-4918 4116

Annexure-A

Additional Details as required under Regulation 30 and other relevant provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015:

Sr. No.	Details of events that needs to be provided	Information of such event(s)
1	Name of the regulatory or licensing authority	Tanzania Bureau of Standards (TBS) under the Ministry of Industry and Trade, United Republic of Tanzania
2	Brief details of the approval/ license obtained/ withdrawn / surrendered	On March 5, 2026, The Company has received confirmation from the Tanzania Bureau of Standards that the manufacturing facility of the Company complies with the acceptable requirements of Good Manufacturing Practices (GMP) as per the criteria applicable for high-risk food products, pursuant to an inspection conducted at the Company's manufacturing facility.
3	Impact/relevance of such approval/ license to the listed entity	The GMP inspection confirmation enables the Company to proceed with registration and approval of its food supplement products in Tanzania, subject to compliance with other applicable regulatory requirements. This is expected to support the Company's international market expansion.
4	Withdrawal/cancellation or suspension of license /approval by the regulatory or licensing authority, with reasons for such action, estimated impact (monetary or otherwise) on the listed entity and penalty, if any	Not Applicable
5	Period for which such approval/ license is/ was valid	5 Years From the date of inspection of the manufacturing facility. (From: December 09, 2025 to: December 08, 2030)
6	Subsequently, the listed entity shall inform the stock exchange(s), the actual impact (monetary or otherwise) along with corrective actions taken by the listed entity pursuant to the withdrawal, cancellation or suspension of the key license/ approval	Not Applicable